The contents of the member listings on the BIO Web site may not be reproduced or used in any form without prior written permission from BIO. For more information about members, please refer to the ...

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on changes announced to the US childhood vaccine schedule.

WASHINGTON, DC (January 7th, 2026) – Today, the Biotechnology Innovation Organization (BIO) announced the launch of the BIO Investment Council (BIC). The newly established council aims to serve small ...

At its simplest, biotechnology is technology based on biology - biotechnology harnesses cellular and biomolecular processes to develop technologies and products that help improve our lives and the ...

Long-term solutions to combating the opioid crisis will depend upon the development of novel and safer, next-generation therapies to treat both pain and addiction. To get these new innovations to the ...

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry's economic ...

The Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) today released new data on the bioscience industry in the United States. The new report, The U.S ...

Democratic lawmakers in the U.S. Senate advanced drug pricing legislation today that would drastically alter the Medicare program. Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology ...

BIO submitted a statement for the record to the Senate Committee on Agriculture, Nutrition and Forestry hearing titled "Farm Bill 2023: Rural Development and Energy Programs." BIO called for a "farm ...

WASHINGTON (March 26, 2025) -- Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical ...

John Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding the resignation of Peter Marks from the FDA: “Under the extraordinary ...

“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the ...